A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.

Joppert MG; Garfield DH; Gregurich MANemunaitis JJMarsland TAKhandelwal PAsmar L

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.

【24h】

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.

机译：二期多中心研究topotecan相结合和吉西他滨作为一线化疗先进的非小细胞肺癌。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by topotecan and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (ANSCLC). Fifty-three patients were enrolled; 51 received treatment. Topotecan 1 mg/m(2), days 1-5 and gemcitabine 1 g/m(2) days 1 and 15 were administered IV, each drug over 30 min; cycles consisted of 28 days. Treatment continued until progressive disease or intolerable toxicity. Nineteen patients (36%) had Eastern Cooperative Oncology Group criteria performance status (ECOG PS) = 0, 34 (64%) PS = 1. Median age was 64 years; 37 patients (70%) were male. Histology: adenocarcinoma (42%), squamous cell carcinoma (28%), large cell (19%), and unclassified (11%). Among 47 evaluable patients, eight (17%) had partial response, 11 (23%) had stable disease. One-year survival was 39% and median survival was 7.6 months (range, < 1-19.6). Grade 3 and 4 toxicities included neutropenia (53%), anemia (18%), thrombocytopenia (12%),asthenia (8%), and gastrointestinal disorders (8%); three patients (6%) experienced neutropenic fever. There were no treatment-related deaths. The combination topotecan/gemcitabine produced a 1-year survival similar to previous platinum-based regimens, when used as first line chemotherapy for ANSCLC. The toxicity profile was acceptable.

机译：这个试验的目的是确定1年存活率、功效和安全、生产的topotecan和吉西他滨作为第一行化疗在晚期非小细胞肺癌症(ANSCLC)。登记;1 - 5毫克/米(2),天,吉西他滨1 g / m(2)天1和15个管理第四,每个药物超过30最小值;一直持续到进步的疾病或无法忍受的毒性。东方合作肿瘤学集团标准性能状态(ECOG PS) = 0, 34 (64%) PS =1. 是男性。鳞状细胞癌(28%),大细胞(19%),和非保密(11%)。患者中,8例(17%)有部分反应,11(23%)有稳定的疾病。39%,平均生存7.6个月(范围,<1 - 19.6)。嗜中性白血球减少症(53%)、贫血(18%)、血小板减少症(12%)、无力(8%)、胃肠道障碍(8%);粒细胞减少性发热。治疗相关的死亡。topotecan /吉西他滨生产一年生存类似于以前的以铂为基础的方案,当用作ANSCLC第一线化疗。毒性是可以接受的。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2003年第2期|215-219|共5页
作者
Joppert MG; Garfield DH; Gregurich MANemunaitis JJMarsland TAKhandelwal PAsmar L;
展开▼
作者单位

US Oncology, Inc, 16825 Northchase Dr, Suite 1300, Houston, TX 77060, USA.;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
Non-Small-Cell Lung Carcinoma; Antineoplastic Agents; gemcitabineTopotecanLung NeoplasmsCarcinoma;

机译：非小细胞肺癌;抗肿瘤药探员;gemcitabineTopotecanLungNeoplasmsCarcinoma;

相似文献

外文文献
中文文献

1. A Phase II Clinical Trial of Celecoxib Combined with Platinum-Based Regimen as First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression [J] . Jun Zhao, Mei-na Wu, Xu-yi Liu, 中国癌症研究（英文版） . 2009,第001期
2. A Phase II Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China [J] . Lu Yang, Zhi-jie Wang, Tong-tong An, 中国癌症研究：英文版 . 2010,第001期
3. Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱 [J] . Clinical cancer research: an official journal of the American Association for Cancer Research . 2009,第18期

机译：Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱
4. Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Catechin; Cell Line, Tumor; Ceramides; Drug Synergism; Enzyme Activation; Humans; Ibuprofen; Male; Mitogen-Activated Protein Kinases; Oxidative Stress; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53;*脱噬作用; Caspase类; 儿茶素; 神经酰胺类; 药物协同作用; 酶激活; 布洛芬; 氧化性应激; 磷酰化; 前列腺肿瘤; 原致癌基因蛋白质 c-bcl-2 [J] . The Netherlands journal of medicine. . 2009,第6期

机译：Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Catechin; Cell Line, Tumor; Ceramides; Drug Synergism; Enzyme Activation; Humans; Ibuprofen; Male; Mitogen-Activated Protein Kinases; Oxidative Stress; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53;*脱噬作用; Caspase类; 儿茶素; 神经酰胺类; 药物协同作用; 酶激活; 布洛芬; 氧化性应激; 磷酰化; 前列腺肿瘤; 原致癌基因蛋白质 c-bcl-2
5. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). [J] . Brandes AA, Tosoni A, Cavallo GBertorelle RGioia VFranceschi EBiscuola MBlatt VCrino LErmani M The British journal of cancer . 2006,第9期

机译：Temozolomide 3周,1星期一线治疗复发性胶质母细胞瘤:phase II study from意大利合作集团neuro-oncologia (GICNO)。
6. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway [O] . Zhang Lijian, Xie Fei, Chen Jinfeng, 2010

机译：iaspp is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.

摘要

著录项

相似文献

相关主题

期刊订阅